Effect of torcetrapib on the progression of coronary atherosclerosis.

By S. Nissen, J. Tardif, S. Nicholls, J. Revkin, C. Shear, W. Duggan, W. Rużyłło, W. Bachinsky, G. Lasala, E. Tuzcu. New England Journal of Medicine, 2007

887 citations recorded by the source corpus.

Subfields: Cancer Research, Endocrinology, Diabetes and Metabolism, Surgery

View Paper: https://www.semanticscholar.org/paper/41f0b18a4a296ddae138e61576881f7b2a71ac67

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Endocrinology, Diabetes and Metabolism

1. K. Wolski
2. Ralph DeFronzo

In Surgery

1. E. Tuzcu

Citations in the corpus

• The Emerging Paradigm of Network Medicine in the Study of Human Disease (2012, background): “102,103 Based on in silico predictions of protein-ligand binding, Xie et al identified a panel of off-targets for torcetrapib and other CETP inhibitors from the human structural genome and mapped those targets to a network of biological pathways curated from the literature.”
• Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. (2008, methodology): “PAV was selected as the primary efficacyparameterbecausethisendpointhas exhibitedthelowestvariabilityinmultiple previous IVUS trials for a diverse range of therapeutic interventions.(10-12,14-16)”